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The Final (Oral Ebola) Vaccine Trial 
on Captive Chimpanzees?
Peter D. Walsh1, Drishya Kurup2, Dana L. Hasselschwert3, Christoph Wirblich2, 
Jason E. Goetzmann3 & Matthias J. Schnell2
Could new oral vaccine technologies protect endangered wildlife against a rising tide of infectious 
disease? We used captive chimpanzees to test oral delivery of a rabies virus (RABV) vectored vaccine 
against Ebola virus (EBOV), a major threat to wild chimpanzees and gorillas. EBOV GP and RABV GP-
specific antibody titers increased exponentially during the trial, with rates of increase for six orally 
vaccinated chimpanzees very similar to four intramuscularly vaccinated controls. Chimpanzee sera also 
showed robust neutralizing activity against RABV and pseudo-typed EBOV. Vaccination did not induce 
serious health complications. Blood chemistry, hematologic, and body mass correlates of psychological 
stress suggested that, although sedation induced acute stress, experimental housing conditions did not 
induce traumatic levels of chronic stress. Acute behavioral and physiological responses to sedation were 
strongly correlated with immune responses to vaccination. These results suggest that oral vaccination 
holds great promise as a tool for the conservation of apes and other endangered tropical wildlife. They 
also imply that vaccine and drug trials on other captive species need to better account for the effects of 
stress on immune response.
In 2014 the world was gripped by fears of an Ebola virus (EBOV) pandemic. Few people realized that Ebola had 
already inflicted pandemic scale mortality on our closest relatives, killing about one third of the world’s gorillas 
and countless chimpanzees (Fig. 1)1,2. African apes are also threatened by naturally occurring pathogens like 
anthrax, SIV (the wild ape progenitor of HIV), and the increasing spillover of human pathogens, not to mention 
rampant commercial poaching and habitat loss3. A glimmer of hope lies in the fact that many of the disease 
threats are vaccine preventable. Unfortunately, traditional hypodermic dart delivery of vaccine is extremely chal-
lenging for animals that live at low density in thick tropical forest and fear humans. A solution to this problem 
is suggested by the use of oral vaccines to virtually eradicate of fox rabies from Western Europe4. Despite the 
astoundingly good safety record of live virus (replication competent) vaccines in the oral rabies program, vocal 
opposition both to the release of genetically modified organisms (i.e. recombinant vaccines) and to the use of 
replication competent vaccines5 has limited oral vaccination of endangered wildlife to a single study published in 
2016: the successful test of an oral rabies vaccine on Critically Endangered Ethiopian wolves6.
By orally vaccinating charismatic apes threatened by the scariest of emergent pathogens we hoped to focus 
further attention on the extent to which conservation concerns may balance fears about vaccine safety: to push 
the debate on orally vaccinating endangered wildlife from an entrenched ideological deadlock towards a scientific 
evidence-based discussion of measurable costs and benefits. Our first step was to conduct trials on oral delivery 
of an EBOV vaccine to captive chimpanzees. We started with a captive trial because host evolutionary similarity 
is strongly correlated with disease susceptibility and vaccine effectiveness7: an effect implied in the fact that sev-
eral early vaccines that were protective against Ebola challenge in mice were not protective in macaques8. Thus, 
management authorities in Africa had scientific justification for insisting that before an EBOV vaccine was used 
on endangered apes in the wild it should be first tested on captive apes.
Here we report results from a trial of the filorab1 vaccine, which inserts the gene encoding the EBOV glyco-
protein (GP) into the replication competent but highly attenuated SAD B19-based RABV vaccine9.We vaccinated 
ten chimpanzees at the University of Louisiana Lafayette’s New Iberia Research Center with 1.5 × 108 focus form-
ing units of vaccine, six orally and four intramuscularly (IM). We chose filorab1 both because it confers robust 
protection to macaques vaccinated IM then challenged with EBOV and because the high safety and effectiveness 
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of the parent rabies vaccine has been exhaustively documented in extensive captive trials on a variety of mammals 
and through distribution of millions of vaccine-laced oral baits in Western Europe10.
The first goal of the trial was to evaluate whether the offspring filorab1 vaccine was immunogenic when deliv-
ered orally to chimpanzees. We did not challenge with EBOV but simply monitored post-vaccination immune 
response by assaying blood drawn on days -8, 0, 7, 14 and 28. New Endangered Species Act (ESA) regulations 
banning invasive research on chimpanzees forced termination of the trial after Day 28. To evaluate immunogenic-
ity we performed enzyme-linked immunosorbant assays (ELISA) of antibodies specific to EBOV GP and RABV 
as well as assays of serum neutralizing activity against RABV and EBOV GP pseudo-typed vesicular stomatitis 
virus (VSV-EBOV).
The second goal of the trial was to evaluate the health impact of the vaccine trial. To quantify the impact of the 
vaccine itself we monitored body mass and a standard panel of hematology and blood chemistry parameters (raw 
data are available in Supplementary Tables S1–3). The hematology and blood chemistry data included several 
variables whose values show well-documented correlations with psychological stress, including white blood cell 
count (WBC) and serum glucose. Our interest in psychological stress was twofold. First, in advocating a ban on 
the use of chimpanzees in biomedical research, animal welfare advocates argued that
“All invasive research is torture. And it’s not just the procedures. It’s the imprisonment. It’s being kept in a small 
space with no choice”11.
We sought both to objectively quantify the level of stress experienced by study chimpanzees and to differenti-
ate between chronic stress induced by social isolation or confinement in small experimental cages and acute stress 
induced by the vaccine or experimental procedures (e.g. sedation or changes in housing). Second, research on 
humans has shown that acute psychological stress can have strong effects on immune function12, most notably a 
stimulatory effect on post-vaccination antibody production13. Although a large literature documents strong stress 
responses of chimpanzees and other captive animals to experimental conditions we could find little published 
work documenting or controlling for the effects of such stressors on captive animal immune response during 
vaccine trials.
Results
Vaccination with filorab1 provoked robust immune responses. EBOV GP-specific antibodies isolated from Day 28 
serum of both oral and IM chimpanzees achieved 50% neutralization of VSV-EBOV at a dilution factor compa-
rable to that Day 28 serum Rhesus macaques who, in a previous study, were IM vaccinated with filorab1 then sur-
vived EBOV challenge (Fig. 2A)14. Chimpanzee serum antibodies also achieved robust neutralization of RABV, 
with all animals showing anti-rabies activity greater than that considered by the World Health Organization to be 
protective against RABV infection (Fig. 2B). For both EBOV and RABV, oral and IM chimpanzees did not differ 
significantly in the maximum dilution at which 50% neutralization was achieved.
Figure 1. Relative health impact of EBOV infection versus sedation for EBOV vaccination. (A) Carcass of 
a chimpanzee killed by EBOV in Odzala-Kokoua National Park, Republic of Congo. (B) Sedated chimpanzee 
being orally vaccinated against EBOV at the New Iberia Research Center, USA.
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ELISA also indicated robust immune responses. In orally vaccinated chimpanzees serum EBOV GP-specific 
immunoglobulin G (EBOV GP-IgG) (Fig. 2C) increased at a rate very close to exponential (Fig. 2), reaching a Day 
28 mean slightly higher than the Day 28 value seen in IM vaccinated Rhesus macaques in the previous study. IM 
vaccinated chimpanzees started the study with slightly higher EBOV GP-IgG than orally vaccinated chimpanzees 
or macaques and reached a Day 28 peak comparable to the Day 35 peak seen in the longer (45 day) macaque 
study. The rate of increase in the EBOV GP-IgG titers of oral chimpanzees accelerated slightly during the trial 
(exponential increase rate Day 0–14 = 0.033, Day 14–28 = 0.052). This later “kick in” of antibody increases in 
orally vaccinated chimpanzees is consistent with the smaller vaccine inoculum introduced into the bloodstream 
through oral vaccination. Projecting the Day 0–28 exponential increase rate forward (Fig. 2C) suggests that oral 
chimpanzees would have reached the peak titers seen in macaques on Day 57 (or Day 51 using the Day 14–28 
increase rate). We could not verify these projections because imposition of the new ESA regulations truncated 
the study.
Vaccinated chimpanzee sera also exhibited robust rises in RABV-specific IgG (r-IgG) (Fig. 2D). IM chim-
panzees showed Day 28 r-IgG titers slightly higher than Rhesus macaques vaccinated with filorab1 in the pre-
vious study. Orally vaccinated chimpanzees again showed lower Day 28 antibody titers than IM chimpanzees 
and macaques but consistent exponential increase during the study (exponential increase rate Day 0–14 = 0.030, 
Day 14–28 = 0.033). Day 28 r-IgG and EBOV-IgG were also highly correlated (Pearson correlation R2 = 0.9, 
p = 0.00003): likely reflecting the total dependence of EBOV antigen growth dynamics on filorab1 (RABV) 
replication.
The psychological pathologies (e.g. repetitive behavior, severe lethargy, self-harm) often seen in vic-
tims of severe trauma, chronic psychological stress or extreme social isolation15 were entirely absent in 
study chimpanzee. On trial Day 0 study chimpanzees did, however, exhibit several well-known correlates of 
hypothalamic-pituitary-adrenal (HPA) axis activation by acute psychological stress16–18, including a small body 
Figure 2. Filorab1 vaccine is strongly immunogenic in chimpanzees. Top Panels: Highest serum 
dilution factor at which serum antibodies isolated from chimpanzees achieved 50% neutralization of (A) 
EBOV pseudotyped VSV and (B) RABV. Red bars IM vaccinated chimpanzees, blue bars orally vaccinated 
chimpanzees. Serum antibodies from all subjects except one IM vaccinated chimpanzee achieved 50% RABV 
neutralization at dilutions much higher than the lowest dilution factor (dashed line in (B) considered by the 
World Health Organization to be robustly protective against RABV challenge. No comparable standard is 
accepted for EBOV. Bottom Panels: ELISA optical densities (OD) for chimpanzee serum titers of IgG against 
(C) EBOV GP and D) RABV. Day 0, 14, and 28 OD’s for 1/150 dilutions of chimpanzee IgG are plotted as a 
proportion of the OD for the positive control: post-challenge IgG from macaques vaccinated with filorab1 in a 
previous study14. Circles are averages for the six orally vaccinated (in blue) and four IM vaccinated (in red)  
chimpanzees. Least squares regression lines through the orally vaccinated chimpanzee data show very close to 
exponential growth of IgG against EBOV GP IgG (R2 = 0.98) and RABV IgG (R2 = 0.99). Error bars are 95% 
confidence intervals (1.96 standard errors). Lack of confidence interval overlap between successive sampling 
days indicates highly significant rises in IgG on Days 14 and 28. RABV IgG titers for orally vaccinated chimpanzees 
grew more slowly than for IM vaccinated chimpanzees or macaques in the previous study (black X’s). EBOV GP 
IgG titers of orally vaccinated chimpanzees grew at a rate similar to that of macaques.
www.nature.com/scientificreports/
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mass loss relative to Day -8 (1.65 kg, paired t-test p = 0.004, Fig. 3A) and rises in serum glucose (p = 0.025, 
Fig. 3B) and white blood cell count (p = 0.04, Fig. 3C). The values of these correlates indicate relatively mild levels 
of stress. For example, a previous study found that 45 days after being taken into captivity wild African green 
monkeys had lost an average of 42% loss body mass19 while peak weight loss was 2% in our study chimpanzees 
(Fig. 3A). Another study20 found that serum glucose peaked at 156 mg/dL 25 days after wild baboons were taken 
into captivity compared to a peak of 123 mg/dL for our study chimpanzees 21 days after being moved from out-
door group housing to indoor experimental housing in paired cages (Fig. 3B). The serum glucose rise observed 
Figure 3. Correlates of acute stress. (A) Mean change in body mass between sedations (1 kg equals 1.4% of 
initial mean body mass). (B) Serum glucose and (D) WBC for ten chimpanzees in this study (red circles), six 
chimpanzees from previous Ebola VLP vaccine study14 (solid black circles), and 26 newly captive baboons20 
(open black circles). Glucose in this study and the baboon study peaked on about the same day and exhibited 
similar baseline levels. Higher peak glucose in baboons is consistent with more severe stress. Chimpanzee WBC 
in this study peaked on Day 0 then plateaued. Chimpanzee WBC in the Ebola VLP study returned to baseline 
by Day 56. WBC not available for baboon study. The three orally vaccinated chimpanzees that presented 
voluntarily for sedation (blue circles) exhibited lower values of (C) glucose and (E) WBC than the three 
that did not always present voluntarily (red circles). Voluntary presenters showed significantly lower serum 
glucose (t test Day 7 p = 0.04, Day 14 p = 0.017) and WBC (Day 7 p = 0.039) than non-voluntary presenters.
(F) Alkaline phosphatase (ALP) in this chimpanzee study and the baboon study peaked on the first sampling 
day then decayed at similar rates to baseline concentrations that were, in both cases, 71% of the peak value, 
suggesting that similar mechanisms down-regulate stress responses in the two species. Baboon values have been 
normalized to the peak chimpanzee concentration to illustrate this similarity. Error bars in all panels are 95% 
confidence intervals (i.e. 1.96 standard errors).
www.nature.com/scientificreports/
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in chimpanzees that voluntarily presented for sedation was particularly modest (from 80 mg/dL on Day -8 to 
106 mg/dL on Day 14) (Fig. 3E): very similar to the values observed in college students anticipating exams21.
Study chimpanzees did not exhibit the immunosuppression often associated with chronic psychological 
stress12. To the contrary, enhanced innate immune activity was indicated by the observed rise in WBC (Fig. 3C). 
What’s more, humoral immune responses were positively correlated with acute stress responses (Fig. 4). In uni-
variate regressions of Day 28 IgG specific to EBOV GP showed strong positive correlation with Day 28 glucose 
Figure 4. Immune responses enhanced by stress. ELISA optical densities (OD) of EBOV GP-specific IgG 
(left column) and RABV-specific IgG (right column) were correlated with three well-known correlates of acute 
stress (A,B) serum glucose, (C,D) WBC, and (E,F) Alkaline phosphatase (ALP). R2 and p value in each plot are 
for univariate least squares regression of each stress correlate versus Day 28 IgG OD at 1:150 dilution. Note that 
IM vaccinated chimpanzees (blue circles) tended to exhibit higher values for all stress correlates. Because of 
correlation between stress variables, multivariate stepwise regression was used to test for independent effects of 
WBC, glucose, and ALP on IgG OD (see main text for results).
www.nature.com/scientificreports/
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(least squares regression R2 = 0.6, p = 0.008) and Day 28 WBC (R2 = 0.57, p = 0.011) and a negative correlation 
with Day -8 ALP (R2 = 0.44, p = 0.036). Day 28 IgG specific to RABV also exhibited positive correlation with Day 
28 glucose (R2 = 0.69, p = 0.003) and Day 28 WBC (R2 = 0.51, p = 0.02) and negative correlation with Day -8 
ALP (R2 = 0.39, p = 0.052). When stress correlate values for each chimpanzee were averaged across the study, 
correlations with Day 28 IgG were slightly weaker but still significant in most cases. We tested for independent 
effects on IgG using stepwise linear regression with a p = 0.05 inclusion threshold. For the single day stress corre-
late data there was not support for inclusion of more than the best fitting predictor variable in the model (glucose 
for both Ebola GP IgG and RABV IgG). However, for the data averaged across sampling days the best model for 
RABV (R2 = 0.93) included both glucose (p = 0.015) and WBC (p = 0.01). A model containing WBC (p = 0.011) 
also came very close to accepting ALP (p = 0.054) as a predictor of EBOV GP. Given the small sample size (10 
individuals), the difference between the predictor variables chosen by stepwise regression probably should not 
be attributed to different functional responses to RABV and EBOV GP but to fairly large variances within three 
variables whose values are all influenced by the same immune processes. That the model predicting individual 
averages (which smooth stochastic variance) had stronger inferential power supports this conclusion.
The chimpanzees that showed the strongest signs of stress at Day 28 were also the most stressed before vacci-
nation. Day 28 values of the best univariate predictor of Day 28 EBOV GP IgG, glucose, were strongly correlated 
with glucose on later days (Day 7 R2 = 0.72, p = 0.02; Day 14 R2 = 0.78, p = 0.007; Day 28 R2 = 0.72, p = 0.02). The 
correlation between Day 0 and subsequent sampling days was weaker for WBC (Day 7 R2 = 0.37, p = 0.06; Day 
14 R2 = 0.44; p = 0.037; Day 28 R2 = 0.15, p = 0.15) but extremely strong for ALP (all days R2 > 0.9, p < 0.00001). 
The fact that high stress values preceded vaccination implies that the correlation between stress and IgG reported 
above was not just a byproduct of the HPA axis arousal that often follows vaccination with replication compe-
tent vaccines. Rather, the causal arrow appears to point in the direction seen in human vaccine trials, from HPA 
arousal by acute stress to enhanced humoral immune response12.
These results raised the possibility that the higher IgG concentration observed in IM chimpanzees were caused 
by more intense anxiety about sedation rather than the larger inoculum sizes delivered via IM vaccination. To 
test this possibility we conducted three separate bivariate regressions of Day 28 IgG, pairing each Day 28 stress 
correlate, S, with a dummy variable representing vaccination mode (IM = 1, oral = 0)
α β γ= + + .OD S IM (1)
To distribute the stress correlate values on a 0–1 scale comparable to the vaccination treatment we trans-
formed the stress value for each individual, i, as
′ =
−
−
.S S S
S S (2)i
i min
max min
With this rescaling the fitted values of α represent the additional Day 28 IgG produced by increasing from the 
lowest to highest stress correlate value. For EBOV GP the best model (R2 = 0.88) included WBC (α = 0.586, 
p = 0.048) and IM (β = 0.725, p = 0.004), implying that the effect of WBC on IgG was 81% as large as that pro-
duced by IM (versus oral) vaccination. For RABV, glucose (α = 0.89, p = 0.041) produced the best fit (R2 = 0.9) 
and had an effect 82% stronger than IM vaccination (β = 0.49, p = 0.061), although under a strict p = 0.05 step-
wise inclusion rule IM would not be included with glucose in the best model. These results imply that stress had 
an impact on IgG concentration at least as large as mode of vaccination.
Discussion
Filorab1’s immunogenicity and lack of side-effects in captive chimpanzees bode well for its use to protect wild 
chimpanzees and gorillas endangered by EBOV. Filorab1 produced immune responses comparable to those 
observed in the only previous EBOV vaccine trial on captive chimpanzees using a virus-like particle (VLP) vac-
cine22 but did so with only one dose rather than the three doses given in the VLP study. Both robust immune 
response to a single dose and oral delivery are massive advantages for the field vaccination of wild apes that are 
difficult to locate in dense forest and fear human approach.
We are already taking further steps towards realizing the potential of oral vaccination as an ape conserva-
tion tool, including ongoing tests of both oral bait prototypes on wild apes and methods for quantifying and 
controlling rates of vaccine bait uptake by both apes and non-target species. Important future steps include heat 
stabilization of vaccine for longer viability under hot forest conditions, non-invasive assays for vaccine safety and 
immunogenicity, and field trials on wild apes. Because of the special position that wild apes hold in the public 
imagination, this work could provide a particularly powerful proof of the more general principle that oral vac-
cination is a safe and efficient way to protect endangered species against a large and growing pathogen threat. 
EBOV challenge experiments on macaques might also be used to establish the protective effect of oral delivery 
of filorab1. However, conservation funds are scarce and the cost of such trials conducting such trials in a BSL4 
facility would likely equal or exceed that of all other activities combined.
It seems likely that further safety and immunogenicity trials on captive chimpanzees will not be part of the 
development program. In principle, research that benefits wild chimpanzee conservation is exempt under the 
new ESA regulations banning medical research on chimpanzees. In practice, all of the biomedical facilities that 
held chimpanzees have or are in the process of “retiring” their populations to sanctuaries: sanctuaries which 
are philosophically opposed to invasive biomedical research. The Pan African Sanctuary Alliance also recently 
voted to oppose biomedical research on chimpanzees at its member institutions. Biomedical research facilities in 
developed countries other than the United States no longer hold chimpanzees. And extensive informal outreach 
suggests that, although zoos have the facilities to conduct safe and rigorous trials and are sympathetic to the con-
servation objectives, they are unwilling to risk the public backlash that hosting vaccine trials might evoke. This 
www.nature.com/scientificreports/
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really may be the final vaccine trial on captive chimpanzees: a serious setback for efforts to protect our closest 
relatives from the pathogens that push them ever closer to extinction in the wild.
This study also has some useful implications for future vaccine trials involving other captive species. First, 
although our relatively small sample size necessitates caution, the results imply that the psychological stress levels 
of captive study animals may modulate the antibody response to vaccination. This is not surprising given both 
published results on the substantial effects of stress on human immune responses and the extensive literature on 
stress responses of captive animals to experimental procedures and housing conditions. It is, however, surprising 
that so little attention seems to have been paid to this phenomenon in the design and analysis of vaccine trials 
involving captive animals. Stress induced variation in immune response is a problem both because it reduces 
inferential power (by introducing variance unexplained by experimental treatments) and because eventual recip-
ients of the vaccine (often humans) will often not be subject to equally high or persistent stress levels. Thus, more 
effort may need to be put into mitigating and controlling for animal stress: both experimentally and statistically. A 
good start would be vaccine trials with larger samples in which sources of stress were experimentally manipulated 
(e.g. oral vs hypodermic immobilization, vaccination without immobilization). The ban on chimpanzee research 
effectively precludes such trials as a part of our ape conservation program.
The second implication of our study is that the key to successfully mitigating and controlling for stress is to 
carefully discriminate between acute and chronic stressors. Much opposition to the use of chimpanzees in bio-
medical research has rested on the assertion that confinement of chimpanzees in small experimental cages during 
trials subjects chimpanzees to psychological stress of a severity comparable to that induced by persistent torture11. 
However, the relatively rapid attenuation of stress responses in our study suggests that chimpanzees did not suffer 
severely from severe, chronic stress due to either confinement in small cages or social isolation. For instance, 
chimpanzees were no longer losing weight by Day 7 and were gaining weight by Day 28 (Fig. 2A). Similarly, WBC 
peaked at Day 0 and serum glucose at Day 14. Furthermore, the longer VLP vaccine trial conducted earlier at New 
Iberia using identical housing and handling protocols showed chimpanzees serum glucose decaying to baseline 
levels by Day 56. In fact, the combined data from the two chimpanzee studies show a pattern of serum glucose rise 
and fall very similar to that seen in baboons acclimating to captivity19 but with a substantially lower peak implying 
less severe stress (Fig. 3B). Chimpanzee titers for alkaline phosphatase, an enzyme whose serum concentration 
responds very quickly to acute stress, peaked at Day -8 and decayed approximately exponentially to near back-
ground level by day 28 (Fig. 3D): a pattern also very similar to that seen in the baboon study.
The relatively quick rise and fall seen in the values of stress correlates suggest that homeostatic mechanisms 
successfully down-regulated the chimpanzee stress responses to experimental conditions. Of particular interest is 
the observation that chimpanzees that did not always voluntarily present for sedation showed mean glucose and 
WBC values respectively 11% and 15% higher than chimpanzees that always voluntarily presented (t test glucose 
p = 0.023, WBC p = 0.033), with glucose and WBC peaks above the lowest daily mean value for non-voluntary 
presenters that were 69% and 46% higher than voluntary presenters. That voluntary presenters showed an earlier 
serum glucose peak (Fig. 3B) could be interpreted as more rapid down-regulation of the stress response to seda-
tion. Results from the earlier VLP vaccine trial show that chimpanzee glucose did not rise (Fig. 3B) or weight drop 
(Fig. 3A) in response to closely-spaced sedations at the end of the study (Days 70, 77, and 84), again consistent 
with down-regulated stress responses to sedation.
These results suggest that contrary to the claims of animal welfare advocates, housing conditions, per se, 
may not be a major source of severe stress in trials on captive primates. Apparently, husbandry improvements 
(e.g. paired cages that allow grooming and other social contact) can successfully minimize social isolation and 
confinement-related stress of the kind responsible for the behavioral and physiological pathologies that originally 
galvanized animal welfare advocates to oppose biomedical testing on non-human primates. Rather, the most 
effective focus of efforts to mitigate stress may be on improved protocols for sedation. For example, sedation stress 
might be reduced by training of study animals to present voluntarily15, distraction tactics23, oral sedatives24, or 
newly developed non-invasive assays of antibodies25 in secreted and excreted body fluids (e.g. urine, saliva, feces). 
Data on the behavioural response to sedation as well as hematological and physiological correlates of stress should 
also be used to statistically control for immune response.
Methods
Study Animals. Ten chimpanzees at the University of Louisiana Lafayette’s New Iberia Research Center were 
randomly assigned to two groups, each having an equal number of males and females. Animals had starting 
weights of 60.25 kg to 87.09 kg and ranged in age from 17 to 30 y. Research was conducted under protocols 
approved by the Institutional Animal Care and Use Committee at the University of Louisiana Lafayette in com-
pliance with the regulations of the USDA Animal Welfare Act. The facility where this research was conducted is 
accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International 
and adheres to principles stated in the eighth edition of the Guide for the Care and Use of Laboratory Animals26.
Vaccine vector. The vaccine vector BNSP333-coZGP (FILORAB1)1 was constructed and recovered as pre-
viously described. FILORAB1 grown and titered on Vero cells with a final titer of 1.5 × 108 focus forming units 
(ffu)/ml.
Immunizations. A total of 10 Chimpanzees were immunized either intramuscularly (IM) (4 animals) or 
orally (6 animals) with 1.5 × 108 ffu of FILORAB1.
Safety Assessments. Chimpanzees were monitored daily and blood was drawn on Days -8, 0, 7, 14, and 
28. On blood collection days, chimpanzees were weighed (Supplementary Dataset 1) and examined for general 
health. Vaccine safety was assessed by monitoring standard hematologic (Supplementary Dataset S2) and blood 
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chemistry (Supplementary Dataset S3) readouts. Hematology analyses were performed using EDTA whole blood 
on an automated hematology analyzer [Beckman Coulter LH780). Reagents were manufactured by Beckman 
Coulter and validated for use on the Beckman Coulter LH780 analyzer. All blood chemistry analytes including 
(Glucose, AST and ALT) were analyzed using serum on an automated chemistry analyzer (Siemens Dimension 
RXL and/or Siemens Dimension Xpand). Reagents were manufactured by Siemens and validated for use on the 
Siemen’s Dimension analyzer. All hematology and blood chemistry parameters were reviewed following facility 
SOPs.
IgG Responses. We used ELISA to test individual chimpanzee and control sera for the presence of IgG spe-
cific to EBOV GP and RABV as described previously27. Post-challenge sera from two Rhesus macaques vacci-
nated with filorab114 were used as controls. Results reported in the main text are for 1:150 dilution of serum IgG.
RABV Neutralizing Antibodies. Sera were heat inactivated at 56 °C for 30 min. Neutralizing activity was 
determined using the rapid fluorescent focus inhibition test (RFFIT) assay as described previously28.
EBOV Neutralizing Antibodies. Sera and control sera were heat inactivated at 56 °C for 30 mins. 2-fold 
dilution of the sera samples starting at 1:5 in serum free medium were prepared in 96 well round bottom plates. 
35 pfu of VSV- VSVΔ G-ZGP-GFP was added to each for 2 hours at 34 °C and transferred to confluent Vero cells in 
96 well plates for another 2 hours at 34 °C. This virus-sera mix was then aspirated from the cells and a 100 μ l/well 
overlay of 0.8% low melting agar in Optimem was added. The plates were placed in a incubator 34 °C for 9 hours 
and fluorescent plaques counted under a microscope. The dilution factor indicating 50% neutralization was 
reported as the neutralizing titer.
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